Inari Medical, Inc. (NASDAQ:NARI) CEO Sells $165,870.00 in Stock

Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $55.29, for a total transaction of $165,870.00. Following the sale, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This represents a 0.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Andrew Hykes also recently made the following trade(s):

• On Tuesday, October 29th, Andrew Hykes sold 3,000 shares of Inari Medical stock. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00.

Inari Medical Stock Up 1.9 %

NASDAQ:NARI opened at $55.45 on Monday. The company has a market capitalization of $3.25 billion, a PE ratio of -41.07 and a beta of 0.97. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $66.61. The stock’s 50 day moving average price is $50.12 and its 200 day moving average price is $48.14.

Wall Street Analysts Forecast Growth

NARI has been the topic of several research reports. Canaccord Genuity Group raised their target price on Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Stifel Nicolaus assumed coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 target price on the stock. Truist Financial increased their target price on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. Robert W. Baird boosted their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 29th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.80.

Hedge Funds Weigh In On Inari Medical

A number of hedge funds have recently modified their holdings of the business. Aigen Investment Management LP acquired a new stake in Inari Medical during the 3rd quarter worth $428,000. Vestal Point Capital LP raised its holdings in shares of Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock valued at $63,922,000 after buying an additional 1,200,000 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in shares of Inari Medical during the second quarter worth about $2,145,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Inari Medical during the third quarter worth about $1,397,000. Finally, Integral Health Asset Management LLC increased its position in Inari Medical by 100.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after acquiring an additional 200,000 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.